Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen

Wanggang Zhang, Fuling Zhou, Xin‐Mei Cao, Yin-Xia Cheng, Aili He, Jie Liu, Xiaorong Ma, Gang Chen
In: Leukemia Research · 2006 · vol. 30(8) , pp. 935–942 · doi:10.1016/j.leukres.2005.11.017 · PMID:16445979 · W2143348483
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper reports the successful treatment of primary refractory anemia using a combination regimen of all-trans retinoic acid, calcitriol, and androgen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We investigated the efficacy and safety of a combination regimen in 63 patients with primary refractory anemia (RA). The daily treatment protocol comprised all-trans retinoic acid (ATRA) (30 mg/m(2)), calcitriol (0.1 microg/m(2)), and androgen (stanozolol 3mg/m(2), or danazol 300 mg/m(2)) in three separate doses for eight consecutive weeks. Hematologic improvement was observed in 43 (68.3%) patients. The treatment administered was generally well tolerated, with no severe regimen-related toxicity. The overall survival rates at 3 and 5 years were 68.72% and 53.18%, respectively. These results indicate that this combination regimen is an effective and well-tolerated treatment for patients with RA.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (71)

Source provenance

openalex
last seen: 2026-05-11T06:41:50.100108+00:00
License: CC0 · commercial use OK